🧬Ask My DNA
Get Started

Heart Health Genetics

Genetic risk factors for cardiovascular disease. Understand how APOE, Factor V Leiden, ACE, MTHFR, and PCSK9 variants affect heart health, cholesterol, and blood clotting risk.

29 articles

Cardiovascular disease remains the leading cause of death worldwide, responsible for roughly 18 million deaths annually. While lifestyle factors like diet, exercise, and smoking play major roles, genetic variants contribute an estimated 40–60% of cardiovascular risk — making genetic testing a powerful tool for early identification and prevention of heart disease.

APOE (apolipoprotein E) is one of the most consequential cardiovascular genes. The three common alleles — E2, E3, and E4 — profoundly affect cholesterol metabolism and cardiovascular risk. APOE E4 carriers have elevated LDL cholesterol and a 2–3× increased risk of coronary artery disease. APOE E4 is also the strongest common genetic risk factor for Alzheimer's disease, making it a gene with dual cardiovascular-neurological significance. Conversely, the E2 allele is generally cardioprotective, associated with lower LDL levels — though it can occasionally cause type III hyperlipoproteinemia in homozygous carriers.

Factor V Leiden (rs6025) is the most common inherited thrombophilia, carried by approximately 5% of people of European descent. This single-nucleotide change makes the Factor V protein resistant to inactivation by protein C, increasing the risk of deep vein thrombosis (DVT) by 3–8× in heterozygous carriers and 50–80× in homozygous carriers. Combined with oral contraceptives, Factor V Leiden creates a multiplicative risk scenario that underscores the clinical value of genetic testing for women considering hormonal birth control.

The ACE gene, encoding angiotensin-converting enzyme, contains an insertion/deletion (I/D) polymorphism that influences blood pressure regulation and cardiac remodeling. The DD genotype is associated with higher ACE activity, increased blood pressure, and greater risk of heart failure — but also enhanced athletic endurance performance, demonstrating the complex trade-offs in cardiovascular genetics. PCSK9, a gene targeted by a new class of cholesterol-lowering drugs, has rare loss-of-function variants that confer naturally low LDL cholesterol and up to 88% reduced coronary heart disease risk.

Lipoprotein(a), encoded by the LPA gene, is an independent and largely genetically determined cardiovascular risk factor that is not adequately captured by standard lipid panels. Elevated Lp(a) affects approximately 20% of the global population and doubles the risk of heart attack and aortic valve disease. Since Lp(a) levels are 80–90% genetically determined, genetic testing provides insights that standard blood tests may miss.

By analyzing your cardiovascular genetic variants through Ask My DNA, you can identify inherited risk factors, understand how your body processes cholesterol and manages blood pressure, and work with your cardiologist on personalized prevention strategies — from targeted screening schedules to evidence-based lifestyle interventions.

We use cookies for analytics. Learn more